StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis USD Growth in Rest of World by Year

USD Growth in Rest of World (% USD) (%)

Novartis USD Growth in Rest of World: 5.0% in FY2025, down 7.0 pts from a year earlier.

Latest, FY2025
5.0%
Period ended Dec 31, 2025
Change on a year earlier
-7.0 pts
12.0% in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below

Where the FY2025 figure comes from

“|| Xolair 3 | Immunology | Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps, food allergy (FA) | 1 723 | 5 | 4 | 1 723 | 5 | 4”

Source: Novartis Form 6-K (0001114448-26-000007) ↗

Reported in Form 6-K & Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedUSD Growth in Rest of World (% USD) (%)Year on yearSource
FY2025Dec 31, 20255.0%-7.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
FY2024Dec 31, 202412.0%+5.0 ptsNovartis Form 6-K (0001370368-25-000007) ↗
FY2023Dec 31, 20237.0%+11.0 ptsNovartis Form 6-K (0001370368-24-000007) ↗
FY2022Dec 31, 2022-4.0%-18.0 ptsNovartis Form 6-K (0001370368-23-000008) ↗
FY2021Dec 31, 202114.0%+7.0 ptsNovartis Form 6-K (0001370368-22-000009) ↗
FY2020Dec 31, 20207.0%-6.0 ptsNovartis Form 6-K (0001370368-21-000008) ↗
FY2019Dec 31, 201913.0%0.0 ptsNovartis Form 6-K (0001370368-20-000007) ↗
FY2018Dec 31, 201813.0%–Novartis Form 6-K (0001370368-19-000006) ↗

Cite this data

StockData. (2026). Novartis USD Growth in Rest of World (%), annual FY2018–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-xolair-row-yoy-usd-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.